March 26, 2014
Dainippon Sumitomo Pharma (DSP) has received Australian regulatory approval for its atypical antipsychotic agent Latuda (lurasidone) for the treatment of adult schizophrenia, the company said on March 25. The Australian Therapeutic Goods Administration granted the marketing authorization for the drug,...read more